Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Barzolvolimab - Celldex Therapeutics Inc

Next Previous
Drug Profile

Barzolvolimab - Celldex Therapeutics Inc

Alternative Names: Anti-KIT monoclonal antibody - Celldex Therapeutics; CDX-0159

Latest Information Update: 16 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Toronto; Yale University School of Medicine
  • Developer Celldex Therapeutics Inc
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Chronic urticaria
  • Phase II Eosinophilic oesophagitis; Prurigo nodularis

Most Recent Events

  • 05 Dec 2025 Celldex Therapeutics initiates the phase III trial for Chronic urticaria (Treatment-experienced) in Germany, Lithuania, Poland, South Africa, Spain, UK and USA (SC) (NCT07266402)
  • 11 Nov 2025 Celldex Therapeutics plans a phase III trial for Cold Urticaria and Familial dermographism (Treatment-experienced) in December 2025 (SC) (NCT07266402)
  • 06 Nov 2025 Efficacy data from a phase II trial in Chronic spontaneous urticaria released by Celldex Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top